ReviewFrontiers in nutrition2026
Vitamin K and muscle health: mechanisms and clinical perspectives in sarcopenia and beyond: narrative review.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin K, a fat-soluble micronutrient traditionally recognized for its role in blood coagulation, has increasingly been implicated as a micronutrient with emerging roles in skeletal muscle health. Experimental and clinical evidence now suggests that vitamin K influences skeletal muscle through both γ-carboxylation-dependent pathways-mediated by osteocalcin, matrix Gla protein (MGP), and growth arrest-specific 6 (Gas6)-and through non-carboxylation mechanisms, including anti-inflammatory, antioxidant, mitochondrial-regulatory, and ferroptosis-suppressing effects. Observational studies associate higher vitamin K intake and status with greater muscle strength, higher muscle mass, and better physical performance among older adults. However, findings from randomized controlled trials (RCTs) remain inconclusive, possibly due to differences in vitamin K isoforms, dosage, intervention duration, and study populations. Beyond age-related sarcopenia, vitamin K may also play a potentially protective role in muscle dysfunction associated with chronic diseases, including dialysis-related cramps and metabolic disorders. This review synthesizes recent mechanistic insights and clinical evidence, highlighting vitamin K as a biologically plausible contributor that is supported primarily by observational and mechanistic evidence for the prevention and management of sarcopenia and other muscle-related disorders, though its role remains incompletely validated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.